Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression

DAN LIN1,2*, GE KUANG2*, JINGYUAN WAN2, XIANG ZHANG1, HONGZHONG LI3, XIA GONG4 and HONGYUAN LI1

1Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University; 2Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing Medical University; 3Molecular Oncology and Epigenetics Laboratory, The First Affiliated Hospital of Chongqing Medical University; 4Department of Anatomy, Chongqing Medical University, Chongqing 400016, P.R. China

Received May 23, 2016; Accepted August 23, 2016

DOI: 10.3892/or.2016.5311

Correspondence to:
Dr Hongyuan Li, Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Chongqing 400016, P.R. China
E-mail: hongy_li@hotmail.com

Dr Xia Gong, Department of Anatomy, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong, Chongqing 400016, P.R. China
E-mail: xiagong5@hotmail.com

*Contributed equally

Abstract. The metastasis of breast cancer is associated with dismal prognosis and high mortality due to the lack of effective treatment. Luteolin, a natural flavonoid compound, has been shown to exert antitumor activity in various types of cancers. However, the effects and mechanisms of luteolin on the metastasis of triple-negative breast cancer (TNBC) remain elusive. In the present study, we found that pretreatment of highly metastatic TNBC cell lines with luteolin dose-dependently inhibited cell migration and invasion, and reversed epithelial-mesenchymal transition (EMT) as determined by altered morphological characteristics, downregulated epithelial markers and upregulated mesenchymal markers, and inhibited EMT-related transcription factors. In an in vivo metastasis experiment using a xenograft model, luteolin markedly inhibited lung metastases of breast cancer and the expression of EMT molecules vimentin and Slug in primary tumor tissues. Notably, luteolin also suppressed the expression of β-catenin mRNA and protein in vitro and in vivo. Furthermore, overexpression of β-catenin by adenoviruses blocked these benefits of luteolin on invasion and metastases of breast cancer. In conclusion, all these results indicated that luteolin effectively suppressed metastases of breast cancer by reversing EMT, which may be mediated by downregulation of β-catenin.

Introduction

Breast cancer is the second leading cause of cancer-related deaths, and the most common cancer among women worldwide (1). Although numerous measures and drugs have been applied to the clinic, metastasis is still one of the most critical issues in patients with breast cancer (2). Therefore, the identification of effective drugs and exploring the mechanisms which suppress breast cancer metastasis may provide hope to clinical therapies.

The metastasis of cancer cells are reminiscent of epithelial-mesenchymal transition (EMT) usually occurring in embryonic development, tissue repair and tumor progression (3,4). During the EMT process, epithelial-like cancer cells lose cell-cell contacts and acquire mesenchymal properties, which are believed to help cancer cells to gain the abilities of migration and invasion, resulting in the disassociation of cancer cells from the primary tumor and migration to distant organs. From a molecular viewpoint, EMT is characterized by downregulation of epithelial cell markers such as E-cadherin and claudin, and upregulation of mesenchymal molecules such as vimentin and N-cadherin (5,6). Several transcriptional factors, including Snail, Slug, ZEB and Twist, have been found to be involved in the regulation of EMT (6,7). These transcriptional factors directly or indirectly repress the transcriptional expression of E-cadherin, resulting in the loss of epithelial markers and the acquisition of mesenchymal features (3). Recent studies have also suggested that EMT is connected with the acquisition of cancer stem cell properties, development of drug resistance, and induction of angiogenesis, providing various distinct benefits to tumor progression (8-12).

Supporting evidence from epidemiology indicates that some natural dietaries may exhibit beneficial actions against the risk or progression of breast cancer (13). Luteolin (Fig. 1A), one of the natural flavonoid compounds found in many plants such as carrots, celery, broccoli, perilla leaf and seed, has...
been reported to possess many biological properties such as anti-inflammatory, anti-allergy, antioxidant, anticancer and anti-microbial (14-16). Previous studies indicate that luteolin exhibits a wide range of antitumor activities in various types of cancers by inhibiting cell proliferation and tumor growth, promoting cancer cell apoptosis and cell cycle arrest, sensitizing drug resistance, and mitigating invasiveness and metastasis of cancer cells (14,17-19). Specifically, it has been found that luteolin enhanced paclitaxel-induced apoptosis in human breast cancer (20), and sensitized drug-resistant human breast cancer cells to tamoxifen (21). Furthermore, luteolin effectively blocked progestin-dependent angiogenesis and the stem cell-like phenotype in human breast cancer cells (22). Although these studies revealed its protective roles in malignancy, the effects and underlying mechanisms of luteolin on the metastasis of highly aggressive triple-negative breast cancer (TNBC) remain largely unexplored.

In the present study, we chose two TNBC cell lines MDA-MA-231 and BT5-49, which have been indicated to possess highly malignant transfer traits (23,24), to investigate the potential functions and mechanisms of luteolin on the metastasis of TNBC in vitro and in vivo.

Materials and methods

Reagents and antibodies. Luteolin (purity >99%) was obtained from Pulus Biology Technology (Chengdu, China). RNA isolation kit, PrimeScript RT and PCR reagent kits were purchased from Takara (Dalin, China). Matrigel and Transwell chambers were obtained from Corning (Corning, NY, USA). Antibodies used in the present study were purchased from the following sources: anti-E-cadherin, anti-claudin, anti-vimentin, anti-N-cadherin, anti-Snail, anti-Slug, anti-ZEB1 and anti-β-catenin antibodies were from Cell Signaling Technology (Danvers, MA, USA); anti-GAPDH antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-Ki67 was from Abcam (Cambridge, UK); anti-F-actin-Red 555 was from Invitrogen (Carlsbad, CA, USA).

Cell culture and treatment. Human breast cancer cell lines MDA-MB-231 and BT5-49 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured at 37°C in Dulbecco's modified Eagle's medium (DMEM) (HyClone, Los Angeles, CA, USA) with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and 1% penicillin/streptomycin in a humidified atmosphere of 5% CO2. The cells were treated with various concentrations (10, 30 and 100 µM) of luteolin for 18 h. The breast cancer cells were observed and the areas of the wound were measured.

Scratch migration assay. MDA-MB-231 and BT5-49 cells were seeded into a 6-well plate in culture medium and allowed to grow to 100% confluence. A sterile toothpick was used to scrape the monolayer cells creating a wound. The scraped cells were washed out with phosphate-buffered saline (PBS), and the remaining cells continued to culture in the absence or presence of different concentration of luteolin for 18 h. The breast cancer cells were observed and the areas of wound were measured.

Transwell invasion assay. The invasion was measured using the Matrigel-coated 24-well Transwell chamber. Briefly, MDA-MB-231 and BT5-49 cells were trypsinized, washed and seeded into the upper chamber in a serum-free medium at a density of 2.5x105 cells/well. The lower chamber contained complete DMEM with 10% FBS. Following incubation for 8 h, the cells on the Matrigel membrane were fixed and stained using crystal violet. The invaded cells were counted.

Immunofluorescent (IF) staining. For IF analysis, the cells or tissues on the slides were fixed in 4% paraformaldehyde at room temperature and permeabilized using 0.05% Triton X-100. Then, the slides were first immersed in blocking solution containing 1% BSA in PBS, followed by incubation with the primary antibody overnight at 4°C. The slides were then incubated in PBS buffer with fluorescently labeled secondary antibody for 1 h at room temperature in the dark. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and observed under a fluorescence microscope (Nikon, Tokyo, Japan).

Protein isolation and western blotting. The cells were lysed in protein lysis buffer to collect total proteins. The concentration of protein was determined using the BCA kit. Total proteins (40 µg) were fractionated on 10% SDS gel, and then transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% BSA in Tris-buffered saline (TBS) containing 0.1% Tween-20, followed by incubation with the primary antibody at 4°C overnight. After washing with TBST for three times, the membranes were incubated with secondary antibody conjugated with horseradish peroxidase (HRP). The membranes were visualized using the enhanced chemiluminescent system and short exposure of the membrane to X-ray film.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Total RNA from the cancer cells was extracted using the RNA isolation kit according to the manufacturer's instructions. Then cDNA was synthesized using PrimeScript RT reagent kit with 1 µg total RNA. qPCR was performed using the PCR kit. The following primer sequences were used: E-cadherin sense, 5'-TCTGGCGCAGATGTAATTGTTGAGA-3'; antisense, 5'-AAAGGGAGCGCCTTTGGG-3'; vimentin sense, 5'-CTTCTGGGGAGTGATAGCCA-3'; antisense, 5'-GGCACACTAAAATAGCAGAGCUCC-3'; and GAPDH sense, 5'-GGCACACTAAATAGCAGAGCUCC-3'; antisense, 5'-GGCACACTAAATAGCAGAGCUCC-3'.

Nude mice and in vivo metastasis assay. Female nude mice at 4-5 weeks old following approval by the Animal Ethics Committee of Chongqing Medical University were housed according to the National and Institutional Guidelines for Humane Animal Care in specific pathogen-free (SPF) laboratory animal environmental. For the xenograft metastasis experiment, female nude mice were subcutaneously injected with 1x106 MDA-MB-231 cells with or without transduction of Ad-GFP or Ad-β-catenin, and subjected to intraperitoneal injection of luteolin (100 mg/kg) three times every week when the tumor reached 1 cm3 in volume. Eight weeks later, the mice were sacrificed under anesthesia. The tumor nodules on the lung were counted. The primary tumor tissues and lung were collected for further analyses.
AGG-3' and antisense, 5'-ACCAGGGAGTGAATCCAG-3'; N-cadherin sense, 5'-AGCCAACCTTAACTGAGGAGT-3' and antisense, 5'-GGCAAGTTGATTGGAGGGATG-3'; Snail sense, 5'-TCGGAAGCCTAACTACAGCGA-3' and antisense, 5'-AGATGAGCATTGGCAGCGAG-3'; Slug sense, 5'-GGGGAGAAGCCTTTTTCTTG-3' and antisense, 5'-TCCTCATTGTTTGTGCAGGAG-3'; GAPDH (control) sense, 5'-TGT TGCCATCAATGACCCCTT-3' and antisense, 5'-CTCCACGACGTACTCAGCG-3'. Relative quantification was achieved by normalization of GAPDH.

Adenovirus transduction. Recombinant adenoviruses Ad-β-catenin or Ad-GFP were transduced into MDA-MB-231 cells according to the manufacturer's instructions. The expression of GFP was used as a marker for monitoring transduction efficiency. After 48 h of transduction, the cells were used for experiments and the target gene expression was also determined by qRT-PCR and western blotting.

Immunohistochemistry (IHC) staining. The expression of molecules which were association with EMT was detected by IHC staining. Briefly, 5-µm thick tissue sections were cut and deparaffinized, and an antigen retrieval procedure was performed. Endogenous peroxidases were quenched by incubating tissue with hydrogen peroxide, followed by incubating with the primary antibody at 4°C overnight and the HRP-labeled secondary antibody sequentially. Finally, the sections were visualized with DAB staining and imaged.

Figure 1. Luteolin inhibits the migration and invasion of breast cancer cells. Triple-negative breast cancer (TNBC) cell lines MDA-MB-231 and BT5-49 were pretreated with various concentrations of luteolin (10, 30 and 100 µM) for the indicated time. (A) Chemical structure of luteolin. (B) The cell migration was determined by wound-healing assay at 24 h after luteolin treatment. (C) The quantification of cell migration. (D) The cell invasion was determined by Transwell invasion assay at 8 h after luteolin treatment. (E) The quantification of cell invasion. The results are shown as the mean ± SD of three experiments, *P<0.05, **P<0.01 compared with the control.
Statistical analysis. All experiments were conducted for at least three independent times. All data are expressed as mean ± SD and the Student's t-test and one-way ANOVA analysis were used to determine significance. P<0.05 was considered significant.

Results

Luteolin inhibits breast cancer cell migration and invasion in vitro. To determine whether luteolin influences breast cancer cell migration and invasion, wound-healing migration and Transwell invasion assays were performed to evaluate the metastasis of breast cancer cell lines MDA-MB-231 and BT5-49. Pretreatment with luteolin resulted in a concentration-dependent slowing of the wound healing ability of breast cancer cells compared with the control group (Fig. 1B and C). The Transwell invasion assay revealed a dose-dependent decrease in cell invasion in the luteolin-treated breast cancer cell lines when compared with the control group (Fig. 1D and E).

Figure 2. Luteolin reverses EMT of breast cancer cells in vitro. TNBC cell lines MDA-MB-231 and BT5-49 were pretreated with various concentrations of luteolin (10, 30 and 100 µM) for the indicated time. (A) Cell morphology was evaluated by phase-contrast microscopy. (B) The cells were subjected to immuno-fluorescence for vimentin and F-actin. (C) The cells were subjected to western blotting for the indicated proteins. (D) The cells were subjected to qRT-PCR for the indicated mRNAs. EMT, epithelial-mesenchymal transition; TNBC, triple-negative breast cancer.
Luteolin reverses EMT in the MDA-MB-231 and BT5-49 cells. As previously stated, the morphology of MDA-MB-231 and BT5-49 cells display a long spindle mesenchymal feature. Following treatment with luteolin, the cancer cell morphology shifted to an oval epithelial type (Fig. 2A). In agreement with this observation, IF assay showed that luteolin downregulated the mesenchymal marker vimentin and reorganized cytoskeletal protein F-actin in the cytoplasm in the two breast cancer cell lines (Fig. 2B). Western blot analysis further showed that levels of epithelial markers E-cadherin and claudin were upregulated, while mesenchymal markers N-cadherin and vimentin with the two EMT-related transcription factors Snail and Slug, particularly Slug, were downregulated in the luteolin-treated breast cancer cells in a concentration-dependent manner (Fig. 2C). Consistently, mRNA expression analysis by qRT-PCR showed similar results with the proteins of EMT (Fig. 2D).

β-catenin is responsible for the anti-migration and anti-invasion effect of luteolin in vitro. In light of the key role of β-catenin in metastasis and EMT of cancer, we determined the expression of β-catenin by western blotting and qRT-PCR. As shown in Fig. 3A and B, compared with the control group, the two breast cancer cell lines expressed higher levels of β-catenin in the luteolin-treated group. In contrast, Ad-β-catenin further enhanced the β-catenin expression levels (Fig. 3C). A wound-healing assay showed that the migration distance of the β-catenin-overexpressing cells was significantly longer than that of the control (Fig. 3C). Similarly, the invasion ability was significantly enhanced in Ad-β-catenin-transduced cells compared to the Ad-GFP group (Fig. 3D).

Figure 3. Luteolin downregulates β-catenin expression to reverse EMT in breast cancer cells. TNBC cell lines MDA-MB-231 and BT5-49 were pretreated with various concentrations of luteolin (10, 30 and 100 µM), and the expression of (A) β-catenin protein and (B) mRNA was determined by western blotting and qRT-PCR, respectively. In the other experiment, MDA-MB-231 cells were transduced with Ad-GFP or Ad-β-catenin, and the cells were subsequently treated with PBS or luteolin (100 µM). (C) The cell migration was determined by wound-healing assay. (D) The cell invasion was determined by Transwell invasion assay. (E) Protein levels and (F) mRNA expression of β-catenin and EMT-related molecules were determined as indicated. The results are shown as the mean ± SD of three experiments; *P<0.05, **P<0.01. EMT, epithelial-mesenchymal transition; TNBC, triple-negative breast cancer.
β-catenin protein and mRNA, which were inhibited by luteolin in a dose-dependent manner. Furthermore, overexpression of β-catenin by an adenovirus vector system was carried out in the breast cancer cell line MDA-MB-231. As shown in Fig. 3C and D, overexpression of β-catenin abrogated the anti-migration and anti-invasion effect of luteolin in the MDA-MB-231 cells. Meantime, we found that these benefits of luteolin on the expression of EMT markers and EMT-related transcription factors were abrogated by overexpression of β-catenin (Fig. 3E and F).

**Luteolin suppresses metastasis of breast cancer cells in vivo.** Finally, we explore the in vivo effect of luteolin on cancer metastasis. As illustrated in Fig. 4A, using a xenograft metastasis tumor model, we found that the prominent metastatic nodules on the surface of the lung were obviously observed in the mice bearing TNBC cells. Luteolin markedly decreased the number of nodules in the lung, which were abrogated by overexpression of β-catenin (Fig. 4B). H&E and Ki67 staining of lungs isolated from the mice receiving orthotopic transplantation displayed that luteolin markedly inhibited breast cancer cell metastases to the lung, while overexpression of β-catenin abolished the inhibitory effect of luteolin on lung metastases of breast cancer (Fig. 4C and D). Noteworthy, the levels of mesenchymal marker vimentin and transcription repressor Slug in the primary tumor tissues were
involved in the regulation of EMT and cancer metastasis, involves the reversion of EMT. These data confirmed that the inhibition of metastasis by luteolin was abrogated by overexpression of β-catenin, indicating that downregulation of β-catenin expression may mediate the inhibitory effects of luteolin on metastasis and EMT of TNBC. Taken together, our experimental data indicated that luteolin exerted a potent therapeutic effect on invasion and metastasis of TNBC, which may be involved in the reversal of EMT by downregulation of β-catenin. These findings suggest that luteolin may be applied as a potential candidate treatment for the prevention and intervention of metastatic breast cancer.

Acknowledgements

The present study was supported by grants from the National Natural Science Foundation of China (no. 81472475). We thank Dr Jianfei Guo, James Winkle College of Pharmacy, University of Cincinnati, OH for the discussion and proof-reading of the manuscript.

References


